Aldeyra Therapeutics Inc (ALDX) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Aldeyra Therapeutics Appoints Chip Clark to Board of Directors

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed...

Form 8-K - Current report

ALDX BREAKING NEWS: BFA Law Announces an Investigation into Aldeyra Therapeutics, Inc. 75% Stock Drop; Investors are Notified to Contact BFA Law

Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for...

Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease

Top-Line Data from Dry Eye Chamber Trial and Field Trial Expected in Q2 2025 Pending Positive Results and Discussions with the FDA, New Drug...

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Aldeyra Therapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed...

Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed...

Form 8-K - Current report